Maximum yearly cost (in €) for an adherence-enhancing intervention to be considered cost-effective. Data from [36, 37, 64].
For Sweden, improvement in medication adherence at 25% should be read at 30%. In Ireland, a longer refill gap period (9-weeks) was selected to define persistence resulting in higher base-case adherence levels.